All In Biotech

Drug Trial Radar · NCT05635708

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

418

Actual

Start

Feb 10, 2023

Primary completion

Dec 19, 2025

Study completion Oct 29, 2026

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Dec 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).

Conditions

  • Non-small Cell Lung Cancer
  • Metastatic Non-small Cell Lung Cancer

Interventions

  • TislelizumabDrug

    Administered by intravenous infusion

  • BGB-A445Drug

    Administered by intravenous infusion

  • LBL-007Drug

    Administered by intravenous infusion

  • CarboplatinDrug

    Investigator's choice; administered by intravenous infusion

  • CisplatinDrug

    Investigator's choice; administered by intravenous infusion

  • pemetrexedDrug

    Investigator's choice; administered by intravenous infusion

  • PaclitaxelDrug

    Investigator's choice; administered by intravenous infusion

  • Nab paclitaxelDrug

    Investigator's choice; administered by intravenous infusion

  • BGB-15025Drug

    Administered Orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed overall response rate (ORR)Time frame: Up to 6 months

Locations

61 sites in 15 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York

  • Providence Portland Medical Center

    Portland, Oregon

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia

  • Northern Beaches Hospital

    Frenchs Forest, New South Wales, Australia

  • Port Macquarie Base Hospital

    Port Macquarie, New South Wales, Australia

  • One Clinical Research

    Nedlands, Western Australia, Australia

  • St John of God Health Care

    Subiaco, Western Australia, Australia

  • Hospital de Amor Barretos

    Barretos, Brazil

  • Hospital Do Cancer de Londrina

    Londrina, Brazil

  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

    Porto Alegre, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    São José do Rio Preto, Brazil

  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira

    São Paulo, Brazil

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Fifth Medical Center of Chinese Pla General Hospital

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Nantong Tumor Hospital Branch North

    Nantong, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University Branch Xianghu

    Nanchang, Jiangxi, China

  • Jining No1 Peoples Hospital East Branch

    Jining, Shandong, China

  • Linyi Peoples Hospital

    Linyi, Shandong, China

  • Affiliated Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai East Hospital Branch Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • Taizhou Hospital of Zhejiang

    Taizhou, Zhejiang, China

  • Institut Curie

    Paris, France

  • Chu Nantes Hopital Nord Laennec

    SaintHerblain, France

  • Arensia Exploratory Medicine Llc

    Tbilisi, Georgia

  • Regina Elena, Istituto Nazionale Dei Tumori, Ifo, Irccs

    Roma, Italy

  • Centro Ricerche Cliniche Di Verona

    Verona, Italy

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.